// App-Quantinova.ai

219 : Safety summary results of baricitinib focusing on serious infections events and preselected comorbidities

Researchers

Presenter

  • Bernard Combe

Principal Investigators

  • Alejandro Balsa

  • Kevin Winthrop

  • Hans-Peter Tony

  • Mark C Genovese

  • Masayoshi Harigai

  • Josef S Smolen

  • Paul Emery

  • Jean Dudler

  • Stephen Hall

  • Cristiano A Zerbini

  • Filip Van Den Bosch

  • Frederick Durand

  • Subhashini Arthanari

  • Veronica Rogai

  • Jinglin Zhong

  • Gabriella Meszaros

  • Maxime Dougados

Medical Centers

  • Rhumatologie, CHRU Montpellier, Montpellier, FRANCE

  • Opthalmology, Hospital Universitario La Princesa

  • Division of Infectious Diseases, Oregon Health and Science University, Portland, OR

  • Rheumatology and Clinical Immunology, Dept. of Medicine 2, University of Wuerzburg, Wuerzburg, GERMANY

  • Canary Center, Stanford University, Palo Alto, CA, USA

  • Department of Pharmacovigilance, Tokyo Women's Medical University, Tokyo, JAPAN

  • Rheumatology, Medical University Vienna, Vienna, -

  • Leeds MSK Biomed, Chapel Allerton Hosp, Leeds, UNITED KINGDOM

  • Service de Rhumatologie, Hôpital Cantonal, Fribourg, SWITZERLAND

  • Cabrini Medical Centre, Cabrini Private Hospital, Malvern, AUSTRALIA

  • CEPIC, Centro Paulista de Investigacao Clinica, Sao Paulo, BRAZIL

  • Rheumatology, UZ Gent, Gent, BELGIUM

  • Biomed, Lilly France, Neuilly-sur-Seine, FRANCE

  • Eli Lilly UK, Eli Lilly and Company Ltd, Basingstoke, UNITED KINGDOM

  • Biomed, Eli Lilly Italia S.p.A., Sesto Fiorentino, ITALY

  • Statistics, Quintiles IMS, Morrisville, NY, USA

  • Biomed, Eli Lilly Ges.m.b.H., Vienna, AUSTRIA

  • Department of Dermatology, Bichat Hospital, Paris, France

Locations

  • France

  • Spain

  • United States

  • Germany

  • Japan

  • Austria

  • United Kingdom

  • Switzerland

  • Australia

  • Brazil

  • Belgium

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Baricitinib

Outcome

  • N/A

Study Design

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved